Initial Management of Branch Retinal Vein Occlusion (BRVO)

Diagnostic Evaluation and Treatment

The American Academy of Ophthalmology recommends comprehensive ocular examination with retinal imaging to assess for macular edema, degree of ischemia, and neovascularization, followed by anti-VEGF injections (ranibizumab or aflibercept) as first-line treatment if macular edema is present causing vision loss 1, 2
The initial examination must systematically evaluate four critical features that determine treatment decisions, including duration and location of vision loss, cardiovascular risk factors, current medications, and prior ocular history 2, 3
Visual acuity testing is essential, as baseline VA is the strongest prognostic factor for final visual outcome 5
Pupillary assessment for relative afferent pupillary defect is crucial, as it corresponds to ischemia severity and predicts neovascularization risk 2, 3, 4

The American Academy of Ophthalmology recommends anti-VEGF intravitreal injections as first-line treatment for macular edema with vision loss, with FDA-approved agents including ranibizumab 0.5 mg or aflibercept 1, 2, 5
Intravitreal corticosteroids are reserved for patients with contraindications to anti-VEGF, with options including triamcinolone or dexamethasone implant, but with a significant risk of secondary glaucoma and cataract formation 1, 2, 5, 6
Sectoral laser photocoagulation to areas of nonperfusion is indicated to prevent vitreous hemorrhage if retinal neovascularization is present 1, 2, 5, 7

Immediate referral to an internist for cardiovascular risk factor optimization is recommended, including control of hypertension, hyperlipidemia, and diabetes 1, 2, 5
Monthly monitoring for the first 6 months is essential to detect complications, including assessment of visual acuity, IOP, and iris/angle for neovascularization 6